身体醜形障害（BDD）市場：パイプライン薬剤評価、臨床試験、競合情勢

当レポートでは、身体醜形障害（BDD）市場について調査し、市場の概要とともに、パイプライン薬剤評価、臨床試験の動向、主要企業、臨床試験プロファイルなどを提供しています。

目次

目次

第1章 序文

第2章 主な調査結果

第3章 病気の情勢

• 病気の概要
• 疫学の概要
• 治療の概要

第4章 上市済み薬剤評価

第5章 価格設定と償還の評価

第6章 パイプライン薬剤評価

第7章 臨床試験の評価

• 歴史的概要
• 概要、相別
• 概要、ステータス別
• 進行中および計画中の臨床試験概要、相別
• 仮想コンポーネントを使用した臨床試験
• 臨床試験概要、地域別
• 単一国および多国籍試験、地域別
• 主要20社のスポンサー内訳、相別
• 主要20社のスポンサー内訳、ステータス別
• エンドポイントステータ別の概要
• 人種および民族別概要
• 地域別サイト概要
• 治験サイトの上位国
• 世界の主要サイト
• 実現可能性分析- 地理的概要
• 実現可能性分析- ベンチマークモデル

第8章 取引の情勢

第9章 商業的評価

• 主要な市場参入企業

第10章 将来の市場促進要因

第11章 付録

Abstract

This reports provides a data-driven overview of the current and future competitive landscape in BDD therapeutics.

• There will be 67,698,071 total prevalent cases of BDD in 2023 in the 16 countries covered in GlobalData's epidemiology forecast.
• No approved marketed drugs are currently available for the treatment of BDD.
• R&D activity within the BDD space is negligible, with no pipeline products in late-stage clinical development.
• Non-commercial sponsors currently dominate the BDD clinical development space.
• No deals were implemented among companies developing BDD assets in the past 24 months.

Scope

GlobalData's Body Dysmorphic Disorder (BDD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Pricing and Reimbursement Assessment
• Pipeline Assessment
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the BDD market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global BDD market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs

5 Pricing and Reimbursement Assessment

6 Pipeline Drugs Assessment

• 6.1 Late-stage Pipeline Drugs
• 6.2 Therapy area-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Overview of Sites by Geography
• 7.13 Top Countries for Trial Sites
• 7.14 Top Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer